Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to chronic kidney disease associated with type 2 diabetes. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated "February 28, 2025".

Types of Enhancements Available

audio
Audio
infographic
Graphical Abstract
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 187    

Filtered results: 187

Diabetes educators: Understanding the role of finerenone in chronic kidney disease associated with type 2 diabetes mellitus

Komé AM, et al. Diabetes Ther. 2025;Online ahead of print.

Komé AM, Yang A, Gee P, et al. , 04 03 2025

Efficacy and safety of finerenone in type 2 diabetes: A pooled analysis of trials of heart failure and chronic kidney disease

Ostrominki JW, et al. Diabetes Care. 2025;Online ahead of print.

Ostrominski JW, Claggett BL, Miao ZM, et al. , 28 02 2025

Change in urine albumin-creatinine ratio and occurrence of hyperkalemia in patients initiating finerenone in the United States: A cohort study from the FOUNTAIN platform

Kovesdy CP, et al. Nephron. 2025;Online ahead of print.

Kovesdy CP, Ebert N, Vizcaya D, et al. , 27 02 2025

Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes, and anemia in FIDELITY

Singh AK, et al. JACC: Advances. 2025;4(2):101524.

Singh AK, James G, Anker SD, et al. , 26 02 2025

COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: Baseline clinical characteristics

Agarwal R, et al. Nephrology Dialysis Transplantation. 2025;Online ahead of print.

Agarwal R, Green JB, Heerspink HJL, et al. , 07 02 2025

Beyond SGLT2: proximal tubule transporters as potential drug targets for chronic kidney disease

Wagner CA, et al. Nephrology Dialysis Transplantation. 2025;40(Supplement_1):i18-i28.

Wagner CA, 05 02 2025

Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease

Neuen BL, et al. Nephrology Dialysis Transplantation. 2025;40(Supplement_1):i59-i69.

Nuen BL, Yeung EK, Rangaswami J, et al. , 05 02 2025

Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease

Alicic RZ, et al. Nephrology Dialysis Transplantation. 2025;40(Supplement_1):i3-i17.

Alicic RZ, Neumiller JJ, Tuttle KR., 05 02 2025

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease

Zhu D, et al. Nephrology Dialysis Transplantation. 2025;40(Supplement_1):i70-i79.

Zhu D, Judge PK, Staplin N, et al. , 05 02 2025

Mineralocorticoid receptor antagonism for non-diabetic kidney disease

Jaisser F, et al. Nephrology Dialysis Transplantation. 2025;40(Supplement_1):i29-i36.

Jaisser F, Barrera-Chimal J. , 05 02 2025